5.05477
MLN4924
≥98% (HPLC), solid, NAE inhibitor, Calbiochem®
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
NAE Inhibitor, MLN4924, ((1S,2S,4R)-4-(4-((1S)-2,3-Dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate, NEDD8-Activating Enzyme Inhibitor, NEDD8-Activating Enzyme Inhibitor, ((1S,2S,4R)-4-(4-((1S)-2,3-Dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulphamate
Empirical Formula (Hill Notation):
C21H25N5O4S
Recommended Products
product name
NAE Inhibitor, MLN4924,
Assay
≥98% (HPLC)
Quality Level
form
solid
potency
4.7 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
light beige
solubility
DMSO: 100 mg/mL
storage temp.
2-8°C
General description
MLN4924 is a specific small molecule NEDD8-activating enzyme (NAE) inhibitor. Neddylation involves adding Nedd8, an ubiquitin-like molecule, to target proteins. This post-translational protein modification is associated with cancer development. MLN4924 is known to induce dose-dependent anti-proliferation, anti-migration, anti-invasion in ccRCC cells. MLN4924 is a cell-permeable AMP mimetic. The mechanism of action is found to target the NEDD8-activating E1 enzyme NAE nucleotide-binding site and undergoes a NAE-catalyzed covalent NEDD8 adduct formation, the adduct in turn acts as a tight-binding, ATP-competitive NAE inhibitor (IC50 = 4.7 nM), exhibiting much reduced or little potency against UAE/UBA1, UBA6/UBE1L2, SAE, ATG7, adenosine receptors A1/A2A/A2B/A3, or a panel of 12 cellular kinases. Selectively reduces cellular Ubc12-NEDD8, but not Ubc9-SUMO or Ubc10-Ub, thioester formation (ICmax = 90 nM in HCT-116 cultures in 24 h), resulting in cullin-RING ligases substrates elevation. Shown to inhibit the growth of various cancer cells both in cultures (IC50 from 50 nM to 1.03 µM) in vitro and in murine xenograft models (30 to 60 mg/kg via s.c.) in vivo via apoptosis induction.
Application
MLN4924 has been used as a neddylation inhibitor:
- to treat cell lines stably expressing a GaLV/MLV chimera construct in order to study its effects on viral transduction and infectivity
- to study its effects on the accumulation of LCMT1, suggesting a potential role in regulating LCMT1 stability and degradation in LNCaP cells
- to study UBX-390-mediated degradation of androgen receptor (AR) via proteasomal action in a prostate cancer cell line
Biochem/physiol Actions
Cell permeable: yes
Primary Target
NEDD8-Activating Enzyme
NEDD8-Activating Enzyme
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Use only fresh DMSO for reconstitution.
Other Notes
Milhollen, M.A., et al. 2010. Blood116, 1515.
Brownell, J.E., et al. 2010. Mol. Cell37, 102.
Soucy, T.A., et al. 2009. Nature458, 73.
Brownell, J.E., et al. 2010. Mol. Cell37, 102.
Soucy, T.A., et al. 2009. Nature458, 73.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Shuai Tong et al.
Scientific reports, 7(1), 5599-5599 (2017-07-19)
Neddylation is a post-translational protein modification associated with cancer development. MLN4924 is a neddylation inhibitor currently under investigation in multiple phase I studies on various malignancies, and its clincal name is Pevonedistat. It has been documented that MLN4924 blocks Cullins
Soohyun Lee et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), e2400398-e2400398 (2024-07-03)
The androgen receptor (AR) is an attractive target for treating prostate cancer, considering its role in the development and progression of localized and metastatic prostate cancer. The high global mortality burden of prostate cancer, despite medical treatments such as androgen
Carolyn A Robinson et al.
Viruses, 14(4) (2022-04-24)
HIV-1 Vpu targets the host cell proteins CD4 and BST-2/Tetherin for degradation, ultimately resulting in enhanced virus spread and host immune evasion. The discovery and characterization of small molecules that antagonize Vpu would further elucidate the contribution of Vpu to
Reyaz Ur Rasool et al.
Nature communications, 14(1), 5253-5253 (2023-08-30)
Loss of the tumor suppressive activity of the protein phosphatase 2A (PP2A) is associated with cancer, but the underlying molecular mechanisms are unclear. PP2A holoenzyme comprises a heterodimeric core, a scaffolding A subunit and a catalytic C subunit, and one
Rizwan Saffie et al.
Cancer research, 80(12), 2498-2511 (2020-05-01)
Mature B-cell neoplasms are the fifth most common neoplasm. Due to significant heterogeneity at the clinical and genetic levels, current therapies for these cancers fail to provide long-term cures. The clinical success of proteasome inhibition for the treatment of multiple
Related Content
Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service